Vector fx logo12/15/2023 Vector BioMed is positioned to take advantage of the significant market need for lentiviral vectors by providing several improved solutions such as algorithm-optimized vectors that enable superior vector titer and function, and a platform serum-free suspension vector manufacturing process that is suitable for rapid clinical development and scalable for commercialization. There is currently an 18–24-month backlog for lentiviral vector manufacturing services. The commercial success of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created an exponential demand for manufacturing capacity and reagents, most notably for custom lentiviral vectors – the preferred method for delivery of genes into therapeutic cellular populations. Our team has decades of experience manufacturing lentiviral viral vectors, providing tremendous value for our partners." "With the FDA granting approval of several gene therapy products, there is now a tremendous demand for the manufacture of lentiviral vectors, which are critical for clinical trials and commercialization. Vector BioMed aims to transform the industry by providing algorithm-optimized, high-titer, and high-quality Lentiviral vectors for partners that seek to move quickly to clinical trials and commercialization. "Now is the perfect time to launch our business," said Dr. Dropulić is also a co-founder and Executive Director of Caring Cross, a non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients. He implemented and directed the company's highly profitable CDMO business model and therapeutic pipeline of gene therapy products. Later he founded Lentigen, which developed the lentiviral vector used to produce Kymriah™, the first FDA-approved gene therapy product. Dropulić led the team that first demonstrated the safety of lentiviral vectors in humans with his colleagues at the University of Pennsylvania. Dropulić brings more than 30 years of leadership and experience in the design, development, manufacturing, clinical translation, regulatory, clinical implementation, and commercialization of Lentiviral vector technology. In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has been named Chief Executive Officer of Vector BioMed.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |